BPC-157Experimental peptide for injury repair

What is BPC-157?

BPC-157 is an experimental peptide discussed in research on injury and tissue repair. Human evidence is limited and does not establish it as a treatment for tendon or ligament injuries.

How it works

In rat tendon-cell and tissue experiments, BPC-157 increased FAK–paxillin signalling and actin-fibre formation, processes that help repair cells attach and move. This is a proposed preclinical repair mechanism, not proof that it regenerates human tendons. 3

Effects studied

Labels: Proven = consistent results in good human trials. Mixed = results point in different directions. Not shown = tested in people without a clear effect, or only in uncontrolled reports. Lab & animal only = no human evidence yet.

What does the evidence show?

Small uncontrolled human reports; preclinical repair research

The question behind the recovery promise

When an injury interrupts training, even a small improvement can feel important. But less pain, repaired tissue and readiness to compete are different outcomes. A useful BPC-157 study would need to tell us which one changed, how much it changed and what happened without treatment.

The human report examined here can guide those questions, but cannot reliably predict the outcome for another injured person.

What the knee-pain report measured

In a 2021 retrospective report, investigators contacted 16 people after treatment: 12 had received BPC-157 alone and four had also received thymosin beta-4. Fourteen reported some pain relief across those groups. Follow-up varied, and the study had no placebo group or standardised outcome questionnaire. 1

That makes the result interesting but difficult to interpret. Pain can change alongside rehabilitation, activity and time. This design cannot separate those influences from a treatment effect, and it did not establish faster tendon or ligament repair. The 14-of-16 figure is not a success rate that can be offered to a new patient.

What would make the answer more useful?

A controlled trial would compare the same injury and rehabilitation programme, then measure outcomes people care about: function, time away from sport, repeat injury and adverse effects. Such a comparison can establish whether a promising treatment helps in a way that a before-and-after account cannot.

The sources checked for this profile do not amount to a comprehensive, up-to-date systematic review. The conclusion is about the evidence examined here; it does not assume that an unproven benefit is impossible.

Why tendon repair is being investigated

In rat tendon tissue and cultured tendon cells, BPC-157 promoted cell migration and tissue outgrowth, with changes in FAK–paxillin signalling. It did not directly increase cell proliferation in the reported assay. These findings give the repair hypothesis a biological basis; whether they translate into stronger or faster-healing human tendons remains a clinical question. 3

Other early human reports

A 2024 uncontrolled pilot in 12 women with interstitial cystitis reported symptom improvement after bladder injections: 10 described complete and 2 partial improvement. These are patient-reported experiences in a small, selected clinic group, not proof of efficacy or evidence about sports injuries. A separate 2025 intravenous safety report followed only 2 adults who had previously received BPC-157. No adverse effects were reported during the brief observation. That cannot establish long-term safety or detect uncommon harms. 4 5

Product identity and safety

The FDA flags immune-reaction and impurity concerns for compounded BPC-157 and describes limited safety information. Its current page places this substance among withdrawn compounding nominations; withdrawal is not approval. 2

A product described as a research chemical does not resolve the questions about its identity, quality or clinical use. This profile therefore links to evidence rather than to sellers or treatment protocols.

Safety & status

The FDA identifies concerns about immune reactions and peptide impurities, with limited safety information. A withdrawn compounding nomination does not constitute approval. 2

Related names & questions

Connections help distinguish compounds and uses; they do not imply equivalent benefits.